Trial Profile
A Placebo-Controlled, Double-Blind, Randomized, Multi-Center Study to Assess the Effects of Dronedarone 400 mg BID for 12 Weeks on Atrial Fibrillation Burden in Subjects With Permanent Pacemakers.
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 15 Apr 2013
Price :
$35
*
At a glance
- Drugs Dronedarone (Primary)
- Indications Atrial fibrillation; Atrial flutter
- Focus Therapeutic Use
- Acronyms HESTIA
- Sponsors Sanofi
- 07 Nov 2012 Results presented at the 85th Annual Scientific Sessions of the American Heart Association.
- 06 Nov 2012 Primary endpoint 'Incidence-of-atrial-fibrillation' has been met.
- 20 Mar 2012 Actual patient number is 112 according to ClinicalTrials.gov.